Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

NCT04363164 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Castration Resistant Metastatic Prostate Cancer

Interventions

DRUG: Testosterone cypionate
DRUG: Enzalutamide
DRUG: Testosterone enanthate

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]